Hoda Kavosi

Dr. Hoda Kavosi


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2022 in BMC Rheumatology
Verified
Journal Article
Open access
PDF file
APAmirhossein Parsaei
Amirhossein Parsaei
SMSoroush Moradi
Soroush Moradi
MMMaryam Masoumi
Maryam Masoumi
FDFereydoun Davatchi
Fereydoun Davatchi
ANAnahita Najafi
Anahita Najafi
HKHoda Kavosi
Hoda Kavosi
Background: Behcet’s disease (BD) as a chronic inflammatory condition that affects the eyes, skin, central nervous system, gastrointestinal tract and vessels. According to the literature, the exact value of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in predicting active manifestations of BD remains controversial. In this study, we aim to assess and compare values of ESR and CRP between BD patients with active/inactive BD and active/inactive manifestations of the disease. Moreover, we try to determine the predictive value of ESR and CRP for disease activity. Methods: Participants (n = 514) were drug-naïve BD patients; Based on last two visits, ESR and CRP values, disease activity, and active manifestations were recorded. The Man-Whitney U test measured the associations, and the binomial logistic regression evaluated the predictive value of ESR and CRP for active disease and each active manifestation. The sensitivity and specificity and the area under the curve (AUC) for each model were determined using receiver operating characteristic curves (ROC). Multiple regressions were run to predict BD activity score from ESR and CRP. Result: Patients with active oral, genital, joint and dermal manifestations had higher ESR and CRP values (Mann–Whitney U test, p < 0.05 for all). Binomial logistic regressions showed that ESR had valuable predictive value for active BD (OR = 1.09 [1.04–1.13], AUC = 0.79 [0.74–0.83], p < 0.001) and active vascular manifestations (1.03 [1.01–1.05], AUC = 0.85 [0.79–0.92], p < 0.001). CRP had good predictive value for active vascular manifestations (OR 1.98 [1.45–2.72], AUC = 0.86 [0.8–0.91], p < 0.001). The optimal value of ESR ≥ 10.5 and ESR ≥ 42.5 could predict active BD and active vascular manifestations with sensitivity, specificity = 71%, 75% and = 81%, 83% respectively. Conclusions: ESR and CRP are both associated with active BD and most manifestations of the diseases. They can be used for the prediction of active BD and active vascular manifestations in BD patients. Further studies can help to confirm the findings of the current research.

22 January 2018 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
NDNavid Dashti
Navid Dashti
MMMahdi Mahmoudi
Mahdi Mahmoudi
FGFarhad Gharibdoost
Farhad Gharibdoost
HKHoda Kavosi
Hoda Kavosi
RRRamazan Rezaei
Ramazan Rezaei
MVMohammad Vodjgani
Mohammad Vodjgani

28 September 2015 in International Journal of Immunogenetics
Verified
Journal Article
Closed access
PDF file
SAS. Abtahi
S. Abtahi
AFA. Farazmand
A. Farazmand
MMMahdi Mahmoudi
Mahdi Mahmoudi
AAA. Ashraf‐Ganjouei
A. Ashraf‐Ganjouei
AJA. Javinani
A. Javinani
FGF. Gharibdoost
F. Gharibdoost

9 June 2021 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
SSSoraya Shadmanfar
Soraya Shadmanfar
MMMaryam Masoumi
Maryam Masoumi
FDFereydoun Davatchi
Fereydoun Davatchi
FSFarhad Shahram
Farhad Shahram
MAMaassoumeh Akhlaghi
Maassoumeh Akhlaghi
ZMZeynab Rastgar Moqaddam
Zeynab Rastgar Moqaddam

23 January 2023 in Modern Rheumatology
Verified
Journal Article
Closed access
PDF file
SNSepehr Nayebirad
Sepehr Nayebirad
AJAli Javinani
Ali Javinani
MJMinoo Javadi
Minoo Javadi
HYHannaneh Yousefi-Koma
Hannaneh Yousefi-Koma
KFKimia Farahmand
Kimia Farahmand
HKHoda Kavosi
Hoda Kavosi
Objectives: In the current study, we aimed to investigate the effect of smoking on inadequate response to methotrexate (MTX-IR) in rheumatoid arthritis (RA) patients.Methods: We searched PubMed, Embase, and Web of Science until 6 June 2022. Observational or interventional studies investigating MTX-IR in RA patients based on smoking status were included. Two independent reviewers assessed the risk of bias and the certainty of the evidence using the Risk of Bias in Nonrandomized Studies–of Interventions and Grades of Recommendation, Assessment, Development, and Evaluation tools, respectively.Results: We included 23 studies in the systematic review and 13 in the meta-analysis. Of the 13 included studies, 6 had a moderate risk, 3 had a serious risk, and 4 had a critical risk of bias. The overall random-effect meta-analysis suggested that smokers were 58% more likely to be MTX-IR when compared with nonsmokers [odds ratio (OR) 1.58, 95% confidence interval 1.21–2.06; P = .001; I2 = 69.3%]. The common-effect meta-analysis of the adjusted ORs demonstrated an overall OR of 2.69 (1.88–3.83; P < .001; I2 = 27.1%).Conclusions: The current study showed that smoking is a significant predictor of MTX-IR, especially in disease-modifying antirheumatic drug–naïve early RA patients, as most of the included studies in the meta-analysis consisted of this population.

29 November 2021 in Clinical Rheumatology
Verified
Journal Article
Open access
PDF file
FSFarhad Shahram
Farhad Shahram
KEKamal Esalatmanesh
Kamal Esalatmanesh
AKAlireza Khabbazi
Alireza Khabbazi
ZRZahra Rezaieyazdi
Zahra Rezaieyazdi
ZMZahra Mirfeizi
Zahra Mirfeizi
SMShayan Mostafaei
Shayan Mostafaei
Objectives To present the clinical characteristics, disease course, management, and outcomes of COVID-19 infection in patients with Behcet’s disease (BD). Methods In this retrospective cohort study, we retrieved BD patients with definite diagnosis of COVID-19 infection. Demographic data, comorbidities, features related both to BD and COVID-19 infection, treatments, and outcomes were collected. Comparisons between patients with or without hospitalization were performed. All statistical analyzes were performed using SPSS version 25. We considered p < 0.05 statistically significant. Results We identified 61 episodes of COVID-19 infection in 59 BD patients. The prevalence was 0.69%. The median age was 45 years (IQR = 20), and the median disease duration was 162 months (IQR = 195). BD features were similar except for higher rate of arterial involvement and positive pathergy test in infected patients. Thirty-five episodes (62.5%) happened in non-active patients; 39% had a comorbid disease. COVID manifestations were the same as the general population. Flu-like symptoms were the most common (85%), followed by fever (66%), ageusia/anosmia (56%), headache (51%), and pulmonary involvement (48%). There was no change in BD symptoms in 74%. Fifteen patients (25.4%) were hospitalized, and one patient (1.7%) died. Receiving glucocorticoids (p < 0.03) and cytotoxic drugs (p < 0.02) were associated with an increased rate of hospitalization. Conclusion The incidence of COVID-19 infection in BD patients was not higher than general population in Iran. They showed milder form of disease with lower morbidity and mortality rate. Most were on immunosuppressive drugs, or had a comorbidity apart from BD. No significant effect on BD course was shown. Key Points • The incidence of COVID-19 infection in patients with Behcet’s disease is not higher. • They showed milder form of infection with lower morbidity and mortality rate. • No significant effect on Behcet’s disease course was shown with COVID19 infection. • BD patients can be managed according to the guidelines used for general population.